Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 9/20 | 0.41 |
| ▸ | ATR | Q13535 | 5/20 | 0.37 |
| ▸ | ATRIP | Q8WXE1 | 5/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14297604 | 1.00 | CXCR3 (0.42) | CXCR3MAPTMTORATRATRIP | |
| SCHEMBL14270947 | 0.85 | MAPT (0.48) | CXCR3MAPTP2RY12 | |
| SCHEMBL14297602 | 0.84 | CXCR3 (0.44) | CXCR3MTORATRATRIPCHEK1 | |
| SCHEMBL14294734 | 0.84 | CXCR3 (0.44) | CXCR3MTORATRATRIPCHEK1 | |
| SCHEMBL14270941 | 0.84 | CXCR3 (0.44) | CXCR3MTORATRATRIPCHEK1 | |
| SCHEMBL14270938 | 0.84 | CXCR3 (0.44) | CXCR3MTORATRATRIPCHEK1 | |
| SCHEMBL14270959 | 0.81 | PIK3CA (0.41) | MTORATRPIK3CA | |
| SCHEMBL14270945 | 0.81 | PIK3CA (0.41) | MTORATRPIK3CA | |
| SCHEMBL14294643 | 0.81 | PIK3CA (0.41) | MTORATRPIK3CA | |
| SCHEMBL14270943 | 0.80 | LCK (0.39) | CXCR3MAPTMTORPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045525-A1 | Piperazinyl-Pyridine Analogues | PRLHR, GPR27, GPR68 | CXCR3 1017/4885MAPT 3839/4885MTOR 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.